DCV+SOF±RBV, VEL/SOF±RBV both effective against genotypes 2, 3 hepatitis C
Treatment regimens containing daclatasvir plus sofosbuvir with or without ribavirin (DCV+SOF±RBV) and the velpatasvir–sofosbuvir combination with or without ribavirin (VEL/SOF±RBV) deliver comparable efficacies against genotypes 2 and 3 hepatitis C virus (HCV) infection, a new study has shown.
Researchers evaluated 44 and 256 patients with genotype 2 HCV who received DVC+SOF±RBV (mean age 62.5±7.0 years 100 percent male) and VEL/SOF±RBV (mean age 63.4±6.4 years; 98.4 percent male), respectively. A total of 514 and 455 genotype 3 HCV patients were also included and were given DCV+SOF±RBV (mean age 60.9±5.6 years; 98.2 percent male) and VEL/SOF±RBV (mean age 61.0±6.7 years; 97.1 percent male), respectively.
Data for sustained virologic response (SVR) were available for 2,774 genotype 2 patients. Among these, 93.9 percent achieved SVR, the rates of which were comparable among those who were given DCV+SOF±RBV (88.1 percent) and VEL/SOF+RBV (89.5 percent; p=1.00). The use of RBV did not lead to statistical improvements in SVR rates.
In comparison, SVR was reported in 90.2 percent of 2,626 genotype 3 patients, for whom the pertinent data were available. Rates were likewise comparable between DCV+SOF±RBV (88.1 percent) and VEL/SOF±RBV (86.4 percent; p=0.51) patients.
Multivariate models showed that a decompensated disease (odds ratio [OR], 0.68; 95 percent CI, 0.47–0.99; p=0.04) and prior HCV treatment (OR, 0.51; 0.36–0.72; p<0.001) significantly reduced the likelihood of SVR in genotype 3 patients. In those with genotype 2 disease, only age <55 years exerted this effect (OR, 0.45; 0.27–0.77; p=0.002).
“The results support current evidence-based guidelines for the use of either DCV+SOF or VEL/SOF as effective treatment options for genotypes 2 and 3,” said researchers.